Corrigendum: Applying new approach methodologies to assess next-generation tobacco and nicotine products

David Thorne; Damian McHugh; Liam Simms; K Monica Lee; Hitoshi Fujimoto; Sara Moses; Marianna Gaca

doi:10.3389/ftox.2024.1460271

Corrigendum: Applying new approach methodologies to assess next-generation tobacco and nicotine products

Front Toxicol. 2024 Jul 19:6:1460271. doi: 10.3389/ftox.2024.1460271. eCollection 2024.

Authors

David Thorne¹, Damian McHugh², Liam Simms³, K Monica Lee⁴, Hitoshi Fujimoto⁵, Sara Moses⁶, Marianna Gaca¹

Affiliations

¹ BAT (Investments) Ltd., Southampton, Hampshire, United Kingdom.
² PMI R&D Philip Morris Products S. A., Neuchâtel, Switzerland.
³ Imperial Brands, Bristol, United Kingdom.
⁴ Altria Client Services LLC, Richmond, VA, United States.
⁵ Japan Tobacco Inc., R&D Group, Yokohama, Kanagawa, Japan.
⁶ Swedish Match, Stockholm, Sweden.

Abstract

[This corrects the article DOI: 10.3389/ftox.2024.1376118.].

Keywords: adverse outcome pathway (AOP); airway models; dosimetry; high-content analysis; human 3D tissues; new approach methodologies (NAM); next-generation products (NGP); organs on a chip (OoC).

Publication types

Published Erratum